Displaying drugs 8051 - 8075 of 8179 in total
REV131
rEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.
Investigational
PRX-07034
Investigational
Epothilone D
Investigational
Annamycin
Investigational
Alicaforsen
Investigational
Refametinib
Investigational
ETC-1001
ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Investigational
AT-527
Investigational
AEOL-10150
AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.
Investigational
RAV12
RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid. RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.
Investigational
Methopterin
Methopterin is thought to have effects on osteoclasts and to inhibit inflammatory bone destruction.
Investigational
Latiglutenase
Investigational
Morphine glucuronide
Investigational
Elvucitabine
Investigational
Inecalcitol
Investigational
Acetylcysteine zidrimer
Investigational
AP1081
A transdermal gel containing ethinyl estradiol and norelgestromin being investigated by Antares Pharma for use as a female contraceptive.
Investigational
Bardoxolone methyl
Investigational
TAS-108
Investigational
Siplizumab
Investigational
Interferon Gamma
Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. The interferon is primarily produced by activated T lymphocytes and natural killer cells.
Investigational
R-348
Investigational
Axatilimab
Axatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
Investigational
PPI-1019
Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.
Investigational
Displaying drugs 8051 - 8075 of 8179 in total